KLRS — Kalaris Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1754068 ·
Last close
$3.40
Market Cap
$80.89M
52W High
$6.25
52W Low
$3.23
ADV30
465,930
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -11,833,000 | -10,856,000 | 109,805,000 | 34,427,000 | 41,248,000 |
| Dec 2025 | 0 | — | -10,801,000 | -9,998,000 | 121,736,000 | 98,054,000 | 42,922,000 |
| Sep 2025 | 0 | — | -12,741,000 | -11,894,000 | 81,175,000 | 42,387,000 | 39,310,000 |
| Jun 2025 | 0 | — | -12,256,000 | -11,350,000 | 92,842,000 | 88,426,000 | 39,727,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-42,510,000
Investing CF
$-35,367,000
Financing CF
$46,045,000
CapEx
$-17,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.23
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-170,855,000
Inventory
—
Receivables
—
ST Investments
$62,788,000
EBIT TTM
$-44,098,000
Pretax Income TTM
$-44,098,000
Interest Exp TTM
$0
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -46,152,000 | -43,438,000 | 121,736,000 | 42,922,000 | — | -38,370,000 |
| Dec 2024 | 0 | -51,732,000 | -69,167,000 | 6,162,000 | 102,778,000 | — | -20,670,000 |
| Dec 2023 | 0 | -13,464,000 | -14,699,000 | 3,333,000 | 48,350,000 | — | -14,132,000 |
| Dec 2022 | 0 | -14,006,000 | -15,485,000 | 3,899,000 | 34,171,000 | — | -9,779,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.63
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CGTX | COGNITION THERAPEUTICS INC | $80.65M | $0.90 | — |
| OKYO | OKYO Pharma Ltd | $86.07M | $1.64 | — |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $75.86M | $5.46 | — |
| PTHS | Pelthos Therapeutics Inc. | $89.46M | $25.74 | — |
| ATRA | Atara Biotherapeutics, Inc. | $72.62M | $8.06 | — |
News headlines (Yahoo Finance, 1h cache)
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
2026-07-20 12:00 · Yahoo
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
2026-07-17 11:00 · Yahoo
Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board
2026-07-14 18:07 · Yahoo
Kalaris Appoints Laurie Keating to Board of Directors
2026-07-06 20:05 · Yahoo
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
2026-06-23 12:00 · Yahoo
Kalaris to Present at Clinical Trials at the Summit 2026
2026-06-12 12:00 · Yahoo
Starbucks upgraded, Doximity downgraded: Wall Street's top analyst calls
2026-05-14 13:45 · Yahoo
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-12 12:00 · Yahoo
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
2026-03-17 12:00 · Yahoo
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
2026-01-28 21:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.